Navigating Challenges and Opportunities: Aquestive Therapeutics' Q3 2025 Earnings Call Highlights

Aquestive Therapeutics reported a net loss of $15.4 million for Q3 2025, a decrease from the previous year. Despite this, the company is well-prepared for Anafilm's potential FDA approval, with marketing materials and a supply chain in place. Anafilm would be the first oral medication for severe allergic reactions, offering a unique alternative to existing auto-injectors and nasal sprays. Aquestive has secured significant financing and expanded its patent coverage, strengthening its competitive position in the market.